Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
daughter accidentally took five doses of Vivotif; daughter accidentally took a Vivotif dose from mother's pack, resulting in mother only getting three doses of Vivotif.; Case reference number US-BN-2025-001077 is a spontaneous case initially received from a consumer via Communication (reference number: USBAV25-1424) on 16-Jun-2025 and concerns two female patients of unknown age (MULTI 2). The patients medical history and concomitant medication details were not provided. On an unknown date, the first patient took first dose of Vivotif (batch number: unknown), at unknown dose, orally for protection against typhoid fever. On an unknown date, the second patient (daughter of the first patient) took first dose of Vivotif (batch number: unknown), at unknown dose, orally for protection against typhoid fever. On an unknown date, an unknown amount of time after the first dose of Vivotif, first patient took second dose of Vivotif (batch number: unknown), at unknown dose, orally. On an unknown date, an unknown amount of time after the first dose of Vivotif, second patient took second dose of Vivotif (batch number: unknown), at unknown dose, orally. On an unknown date, an unknown amount of time after the second dose of Vivotif, first patient took third dose of Vivotif (batch number: unknown), at unknown dose, orally. On an unknown date, an unknown amount of time after the second dose of Vivotif, the second patient took third dose of Vivotif (batch number: unknown), at unknown dose, orally. On an unknown date, an unknown amount of time after the third dose of Vivotif, the second patient took fourth dose of Vivotif (batch number: unknown), at unknown dose, orally. On an unknown date, an unknown amount of time after the fourth dose of Vivotif, the second patient accidentally took a dose from her mother's pack, which was fifth dose of Vivotif (batch number: unknown), at unknown dose, orally (explicitly coded as: 'accidental overdose'), due to this first patient missed a fourth dose of Vivotif to receive (explicitly coded as: 'missed dose'). At the time of the initial report, it was unknown if the patients experienced any adverse event due to Vivotif. Additional information received from consumer via Comm on 16-Jun-2025. New information included Comm reference: USBAV25-1426.; Reporter's Comments: A female patient of unknown age accidentally took a dose from her mother's pack, which was fifth dose of Vivotif, which is considered as accidental overdose, and due to this the first patient missed a fourth dose of Vivotif to receive, which is considered as missed dose. It was unknown if the patients experienced any adverse event due to Vivotif. Accidental overdose and product dose omission issue are considered as listed per company convention. The patients' medical history and concomitant medication details were not provided. Accidental overdose and product dose omission issue are not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unknown age accidentally took a dose from her mother's pack, which was fifth dose of Vivotif, which is considered as accidental overdose, and due to this the first patient missed a fourth dose of Vivotif to receive, which is considered as missed dose. It was unknown if the patients experienced any adverse event due to Vivotif. Accidental overdose and product dose omission issue are considered as listed per company convention. The patients' medical history and concomitant medication details were not provided. Accidental overdose and product dose omission issue are not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.